Sensei Biotherapeutics, Inc. Common Stock
SNSESensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. The company specializes in designing vaccine and antibody-based treatments to target underlying mechanisms of cancer and improve immune response. Its proprietary platform aims to address unmet needs in cancer care through personalized and novel immunotherapies.
Company News
A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—a...
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising ca...
Sensei Biotherapeutics surged 230% on Wednesday following its acquisition of Faeth Therapeutics and a concurrent $200 million private investment. The deal brings PIKTOR, an investigational oral combination targeting the PI3K/AKT/mTOR pathway, into Sensei's pipeline. The company plans to advance PIKTOR through Phase 2 trials in advanced endometria...
Sensei Biotherapeutics announced promising Phase 1/2 trial results for solnerstotug, a monoclonal antibody targeting VISTA, showing 50% 6-month progression-free survival in PD-(L)1 resistant tumors at the 15 mg/kg dose, with plans to advance to Phase 2 studies in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from exi...
